Nefrologia, Dialisi e Trapianto - Gruppo di Ricerca

• Cell therapy with Mesenchymal Stromal Cells (MSC) and/or with Extracellular Vesicles derived from MSC (EV) in in vitro model and in ex vivo and in vivo animal (rat and pig) models of renal diseases and transplantation.
• Graft conditioning with MSC, EV and experimental drugs in animal and human models of marginal organs transplantation (DCD/ECD). 
• New drug delivery strategies in organ conditioning before transplantation.
• Extracorporeal photopheresis (ECP) innovative treatment in transplanted patients with chronic renal antibody rejection and transcriptomics studies on the mechanisms underlying the ECP therapeutic effect through Nanostring technology.
• miRNA profile to evaluate the cancer risk in transplanted patients.
• Studies on humoral and cellular immune response against virus (CMV, EBV, VZV, SARS-CoV2) and predictive markers of the bacterial/viral infections risk in transplanted and uremic patients
• Cross-talk kidney-gut in dialysis patients: Impact of dialysis biocompatibility and microbiome variation on immune/inflammatory state and survival of uremic patients.

• Grignano MA, IJMS, 2022;

• Rampino T, Biology, 2022;

• Gregorini M, Transpl Int, 2022;

• Gregorini M, Biology, 2021;

• Gregorini M, Mayo Clin Proc, 2013.

 Nanostring technology ;Nanosight technology; Molecular, cellular and immune-histological technologies; organ perfusion technology.

IRCCS Fondazione Policlinico San Matteo di Pavia; Pharmaceutics societies.

University of Pavia; University of Genoa; University of Turin; University of Naples; University of Bari; Policlinico Sant’Orsola Malpighi of Bologna; University of Texas; University of Columbia (USA).